Printer Friendly

Quantum Genomics Corp Opens European HQ in Paris Region.

JERSEY CITY,N.J. -- Quantum Genomics Corp (QGC), a global biotechnology company seeking to transform the discoveries and developments of academic research into breakthrough treatments for human disease, announces today that it has chosen to set up its European headquarters in Massy, close to Paris. Lionel Segard, recently appointed CEO of the parent company, will be President of the new European subsidiary.

The choice of Massy, an area just south of Paris that has a high concentration of technology activities, will facilitate the identification and development of innovative projects in the field of human health. The offices are already operational and are the base from which the company will recruit key members of staff, network with European scientists, and generally develop the business.

"The opening of QGC's European offices is the first major step in developing our activities," said Segard. "It is important to have a base in Europe from which to build and maintain close contact with European scientists to bring to maturity healthcare projects."

"This move sends QGC on its way to becoming a significant international player," said Jonathan McCann, board member of QGC. "Our European presence will be a bridge between the two regions in the world which have the most dynamic health research activities, and will increase the chances of bringing this research to a successful conclusion."

About Quantum Genomics Corp.

Quantum Genomics Corp. (QGC), Jersey City, New Jersey, is a global biotechnology company seeking to transform the discoveries and developments of academic research into breakthrough treatments for human disease. The company has unique expertise in the detection and selection of highly promising life science projects. It co-develops products with academic teams. It also develops public/private partnerships to speed up the process of research/development to turn basic research into products. QGC initial areas of interest and expertise are in cardiovascular diseases, neurology, and metabolism-related diseases. QGC's strategic alliances and business partnerships will include disease-oriented therapeutic collaborations, technology transfer-agreements, and marketing/licensing agreements in the fields of recombinant proteins, monoclonal antibodies, and advanced chemical compounds.

For more information go to
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:4EUFR
Date:Jul 3, 2006
Previous Article:Washington Mutual, Inc. Announces the Convertibility of New American Capital, Inc. 4% Convertible Senior Notes Due May 15, 2008.
Next Article:The India Fund, Inc. Announces Commencement of Rights Offering.

Related Articles
Louis de Broglie, 1892-1987.
Corporations increase use of executive suites.
HQ Business Centers launched Long Island expansion at EAB.
HQ Business Centers offers upscale address at affordable prices on LI.
Planned to be unveiled at the Paris Air Show, Flir Systems has developed its Ultraforce II multiple payload, high-performance flir.
2004 Supply Excellence Awards.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters